{
  "patent_number": "US 20160168227",
  "country": "US",
  "title": "Composition and vaccine for treating lung cancer",
  "original_title": "Composition and vaccine for treating lung cancer",
  "summary": "",
  "what_it_does": "The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.",
  "what_it_does_not_cover": [],
  "filed": "2016-02-19",
  "granted": null,
  "expires": "2036-02-19",
  "status": "active",
  "holder": "Curevac AG",
  "holder_url": "https://patentbrief.org/company/curevac-ag",
  "inventors": [
    {
      "name": "Karl-Josef Kallen",
      "url": "https://patentbrief.org/inventor/karl-josef-kallen"
    },
    {
      "name": "Ulrike Gnad-Vogt",
      "url": "https://patentbrief.org/inventor/ulrike-gnad-vogt"
    },
    {
      "name": "Mariola Fotin-Mleczek",
      "url": "https://patentbrief.org/inventor/mariola-fotin-mleczek"
    }
  ],
  "times_cited": 80,
  "tags": [],
  "abstract": "The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.",
  "url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer",
  "markdown_url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer/md",
  "google_patents_url": "https://patents.google.com/patent/US20160168227",
  "relatedPatents": []
}